Cambridge Antibody Technology Group plc plans to acquire Oxford GlycoSciences plc in an all-share deal valuing OGS at £109.6 million (US$177 million). The deal would create a company with a £260 million cash pile and a market capitalization of around £289 million. (BioWorld Today)